Poor prognosis of intra‐tumoural TRBV6‐6 variants in <i>EGFR</i> ‐mutant NSCLC: Results from the ADJUVANT‐CTONG1104 trial-Reference-Cited by-同舟云学术

Poor prognosis of intra‐tumoural TRBV6‐6 variants in EGFR ‐mutant NSCLC: Results from the ADJUVANT‐CTONG1104 trial

Published:2022-04 Issue:4 Volume:12 Page:
ISSN:2001-1326
Container-title:Clinical and Translational Medicine
language:en
Short-container-title:Clinical & Translational Med

Author:

Chen Cunte¹^ORCID,Liu Siyang Maggie¹²³^ORCID,Chen Yedan⁴^ORCID,Han Ming⁴,Ou Qiuxiang⁴^ORCID,Bao Hua⁴^ORCID,Xu Ling¹^ORCID,Zhang Yikai¹^ORCID,Zhang Jia‐Tao⁵^ORCID,Zhong Wenzhao⁵^ORCID,Zhou Qing⁵^ORCID,Yang Xue‐Ning⁵^ORCID,Shao Yang⁴⁶^ORCID,Wu Yi‐Long⁵^ORCID,Liu Si‐Yang⁵^ORCID,Li Yangqiu¹^ORCID

Affiliation:

1. Key Laboratory for Regenerative Medicine of Ministry of Education Institute of Hematology School of Medicine Jinan University Guangzhou China

2. Department of Hematology First Affiliated Hospital The Clinical Medicine Postdoctoral Research Station Jinan University Guangzhou China

3. Chinese Thoracic Oncology Group (CTONG) Guangzhou China

4. Geneseeq Research Institute Nanjing Geneseeq Technology Inc. Nanjing China

5. Guangdong Provincial Key Laboratory of Translational Medicine in Lung Cancer Guangdong Provincial People's Hospital Guangdong Academy of Medical Sciences Guangdong Lung Cancer Institute Guangzhou China

6. School of Public Health Nanjing Medical University Nanjing China

Funder

National Natural Science Foundation of China

China Postdoctoral Science Foundation

Publisher

Wiley

Subject

Molecular Medicine,Medicine (miscellaneous)

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ctm2.775

Reference10 articles.

1. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial